New hope for lymphoma patients when CAR-T therapy Isn't enough
NCT ID NCT06760156
Summary
This study is testing whether a combination of two drugs (tafasitamab and lenalidomide) can help people with large B-cell lymphoma who still have cancer after receiving CAR-T cell therapy. The research aims to see if this treatment is safe and effective at eliminating or reducing the remaining cancer. About 28 adults who meet specific health criteria will participate for approximately 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.